Charlotte Graham

Ms. Charlotte Graham

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CGCharlotte Graham
Charlotte Graham
Erin BarkerErin Barker
Erin Barker
JMJoe William Edward Moss
Joe William Edward Moss
EGEmily Gregg
Emily Gregg
RMRachael McCool
Rachael McCool
MTMaribel Tribaldos
Maribel Tribaldos
The dynamic nature of infectious diseases introduces inherent challenges to the design of vaccine clinical trials, which consequently makes vaccine indirect treatment comparisons (ITCs) and meta-analyses (MAs) more challenging compared with regular pharmaceuticals. However, comparisons of efficacy and safety between vaccines are being frequently required in vaccine decision making due to a low number of head-to-head clinical trials in the vaccine landscape. The introduction of the European Union Health Technology Assessment (HTA) Regulation (EU HTAR) aims to harmonize HTA efforts across Europe. However, the EU HTAR could also escalate existing challenges for conducting vaccine MAs and ITCs. Such challenges include generating efficacy evidence in time for Joint Clinical Assessment (JCA), incorporating high levels of heterogeneity due to infectious disease-specific characteristics, and tackling a high number of PICOs per submission—likely driven by heterogeneity in the available data and differences in national vaccine calendars. Opportunities to tackle these challenges include introducing a stepwise approach to vaccine assessment in JCA, best-practice recommendations for conducting/interpreting vaccine MAs and ITCs, and condensing the number of PICOs to create larger ‘catch-all’ ITC networks. This perspective article explores these challenges and opportunities further.

12 June 2025 in The European Journal of Health Economics
Verified
Journal Article
Closed access
PDF file
Matthew TaylorMatthew Taylor
Matthew Taylor
JGJoe Goldbacher
Joe Goldbacher
CGCharlotte Graham
Charlotte Graham
JMJames Mahon
James Mahon
MCMike Chambers
Mike Chambers

1 April 2026 in Patient Related Outcome Measures
Verified
Journal Article
Open access
PDF file
ASAdam Smith
Adam Smith
TBTom Bromilow
Tom Bromilow
SMStuart Mealing
Stuart Mealing
CGCharlotte Graham
Charlotte Graham
DLDamian Lewis
Damian Lewis
ADAudrey DunnGalvin
Audrey DunnGalvin
Purpose: Health-related quality of life (HRQoL) measures in the form of health utilities are valuable for economic evaluations of the effectiveness of food allergy interventions. However, traditional HRQoL instruments lack the sensitivity to generate health utilities that capture the impact that food allergies, such as peanut allergies, may have on children’s mental health and daily activities. This study used mapping and discrete choice experiment (DCE) methods to generate health utilities from the Food Allergy Quality of life Questionnaire–Parent Form (FAQLQ-PF), which were then applied to clinical trial data. Patients and Methods: Health utilities (HU) were generated using two methods: mapping and DCE. Parents of children with peanut allergies (N=159) completed the FAQLQ-PF and EQ-5D-Y-Proxy-1 questionnaires. Mapping algorithms were developed once the FAQLQ-PF responses were mapped onto the EQ-5D-3L utilities. A composite DCE with time trade-off and a vignette was conducted among parents without peanut allergic children (N=767). The utilities derived from the mapping and DCE methods were applied to clinical trial data (PEPITES and PEOPLE) for an epicutaneous peanut patch (DBV712). Results: The mapping algorithm showed an association of 0.199 between FAQLQ-PF and EQ-5D-3L utilities. The DCE disutilities were highest for severe food-related anxiety, emotional distress, and social limitations. Once applied to the clinical trial data, the HU derived from the mapping algorithm demonstrated statistically significant HRQoL improvements for the intervention group at 36 months. Using the DCE-derived utilities, statistically significant HRQoL improvements for the intervention group were demonstrated at both 24- and 36-months. The effect size analysis demonstrated that the DCE-derived utilities were more responsive than mapped utilities. Conclusion: DCE-derived utilities demonstrated greater responsiveness to changes in HRQoL compared with mapped utilities, suggesting their potential use in economic evaluations and HTA submissions for peanut allergy interventions. The DCE-derived health utilities showed greater sensitivity to changes in HRQoL. These utilities can be used in health technology assessments to better capture the impact of peanut allergy treatments on children’s quality of life.

18 October 2024 in JMIR Preprints
Verified
Preprint
Open access
LKLaura Kelly
Laura Kelly
CGCharlotte Graham
Charlotte Graham
RNRebecca Naylor
Rebecca Naylor
MGMaisie Green
Maisie Green
HHHayden Holmes
Hayden Holmes
KCKerstyn Comley
Kerstyn Comley
BACKGROUND Digital peer-support apps can support people with mental ill-health and are an alternative option to traditional NHS resources. Tellmi is a peer-support app for CYP with mental ill-health. OBJECTIVE This paper sought to create an early economic evaluation of Tellmi. METHODS A questionnaire was shared with Tellmi users to collect demographic data and establish healthcare resource use over a period of three months. This informed the development of an early cost-comparison model, which captures the difference in costs and resource use of CYP who use Tellmi compared with the standard of care. A one-year time horizon was used, and the model was built from an NHS perspective. Deterministic sensitivity analysis was conducted to highlight which parameters are key drivers. RESULTS The survey collected 283 responses from Tellmi users. There were significantly fewer visits to A&E, GP’s and school nurse/counsellor after use of Tellmi for more than one month compared with the standard of care. An early cost calculator model was built to estimate the impact of Tellmi on NHS England. The model estimated that using Tellmi led to a cost saving of £159 (including Tellmi’s basic service cost) to £214 per person (excluding Tellmi’s basic service cost). CONCLUSIONS This study indicates that Tellmi has the potential to be cost saving to the NHS. We recommend further evidence collection including medium- to long-term follow up to reduce the uncertainty in future evaluations of Tellmi. This study indicates that Tellmi has the potential to be cost saving to the NHS. We recommend further evidence collection including medium- to long-term follow up to reduce the uncertainty in future evaluations of Tellmi.

12 August 2026 in Applied Health Economics and Health Policy
Verified
Journal Article
Open access
PDF file
JBJamie Bainbridge
Jamie Bainbridge
SMStuart Mealing
Stuart Mealing
CGCharlotte Graham
Charlotte Graham
MJMathias Jenal
Mathias Jenal
NDNicolas von Dombrowski
Nicolas von Dombrowski
Amy DymondAmy Dymond
Amy Dymond
Background RSVpreF is a vaccine that immunises against respiratory syncytial virus (RSV), a seasonal respiratory virus, that can lead to lower respiratory tract infections. In Switzerland, RSVpreF is indicated for the passive protection of infants against RSV following maternal immunisation. Objective The Swiss Federal Office of Public Health commissioned a health technology assessment (HTA) of RSVpreF for maternal vaccination, evaluating the clinical and cost effectiveness of the vaccine compared with nirsevimab (administered directly to newborns and infants) or no RSV prophylaxis. This study reports the cost-effectiveness model developed for the Swiss HTA. Methods The model used a Markov model structure, a 1-year time horizon, a one-month cycle length, a Swiss healthcare payers' perspective, and a 3% discount rate for costs and health benefits. Health states included no RSV infection, RSV infection leading to hospitalisation, primary care visits or emergency department visits, post-RSV infection, and death. MATISSE informed RSVpreF efficacy, and MELODY and HARMONIE informed nirsevimab efficacy. Health outcomes were expressed as quality-adjusted life years (QALYs). Probabilistic and deterministic sensitivity analyses were undertaken to explore the impact of parameter uncertainty on the model results. Results When compared with nirsevimab, RSVpreF reduces total costs (CHF −9,878,738) and QALYs (−18.4), with an incremental cost-effectiveness ratio (ICER) of 536,008 per QALY (N = 38,844). Compared with no RSV prophylaxis, RSVpreF increases total costs (CHF +470,441) and QALYs (+27.1), with an ICER of 17,377 per QALY (N = 38,844). Conclusions RSVpreF is highly likely to be cost-effective versus both comparators at a range of plausible threshold values. The results of the model contributed to guidance updates in Switzerland, with RSVpreF now reimbursed by mandatory health insurance.

18 July 2024 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
SMStuart Mealing
Stuart Mealing
EGEmily Gregg
Emily Gregg
CGCharlotte Graham
Charlotte Graham
ASAdam Smith
Adam Smith